Skip to Content
Merck
CN

Key Documents

View All Documentation

V4890

Vindesine sulfate salt hydrate

≥95% (HPLC)

Synonym(s):

3-(Aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine sulfate salt hydrate, Desacetylvinblastine amide sulfate salt hydrate

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C43H55N5O7 · H2SO4 · xH2O
CAS Number:
59917-39-4
Molecular Weight:
852.00 (anhydrous basis)
UNSPSC Code:
12352200
PubChem Substance ID:
329829055
NACRES:
NA.77
Assay:
≥95% (HPLC)
Form:
powder
Quality level:
100
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

assay

≥95% (HPLC)

form

powder

color

off-white to light yellow

solubility

deionized water: ≥50 mg/mL

originator

Eli Lilly

storage temp.

−20°C

SMILES string

O.OS(O)(=O)=O.CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C2)(C(=O)OC)c5cc6c(cc5OC)N(C)[C@H]7[C@](O)([C@H](O)[C@]8(CC)C=CC[N@H]9CC[C@]67[C@H]89)C(N)=O)C1

InChI

1S/C43H55N5O7.H2O4S.H2O/c1-6-39(52)21-25-22-42(38(51)55-5,33-27(13-17-47(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)54-4)46(3)35-41(28)15-18-48-16-10-14-40(7-2,34(41)48)36(49)43(35,53)37(44)50;1-5(2,3)4;/h8-12,14,19-20,25,34-36,45,49,52-53H,6-7,13,15-18,21-24H2,1-5H3,(H2,44,50);(H2,1,2,3,4);1H2/t25-,34+,35-,36-,39+,40-,41-,42+,43+;;/m1../s1

InChI key

TUDLKTILIBRXNU-RIHOAIHNSA-N

Related Categories

Biochem/physiol Actions

Microtubule inhibitor
Microtubule inhibitor. Vindesine binds to and stabilizes tubulin, thereby preventing tubulin polymerization, preventing mitosis, and arresting cells in metaphase.

Features and Benefits

This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000380562
0000380562
0000078262
0000078263
056M4730V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

René-Olivier Casasnovas et al.
Blood, 118(1), 37-43 (2011-04-27)
The prognostic value of interim positron emission tomography (PET) interpreted according to visual criteria is a matter of debate in diffuse large B-cell lymphoma (DLBCL). Maximal standardized uptake value reduction (ΔSUVmax) may better predict outcome. To compare the prognostic value
Haoyuan Zhang et al.
Internal medicine (Tokyo, Japan), 51(12), 1537-1542 (2012-06-26)
We report two cases of membranoproliferative glomerulonephritis, involved in Castleman's disease of hyaline vascular variant and mixed variant, respectively. The diagnoses were confirmed by cervical lymph node and renal biopsy. Both cases were sensitive to chemotherapy with cyclophosphamide, vindesine and
Katrin Patrij et al.
German medical science : GMS e-journal, 9, Doc11-Doc11 (2011-06-24)
We analyzed clinical outcome of patients with an isolated central nervous system lymphoma (CNSL) relapse after systemic non-Hodgkin's lymphoma (NHL). All 23 patients with an isolated secondary CNSL (SCNSL) treated at two institutions from 04/2003-12/2007 were included into this analysis.
N Ketterer et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 24(4), 1032-1037 (2012-12-14)
The superiority of a chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (ACVBP) in comparison with cyclophosphamide, doxorubicin, vincristin and prednisone plus radiotherapy for young patients with localized diffuse large B-cell lymphoma (DLBCL) was previously demonstrated. We report the results
Intensified chemotherapy for diffuse large B-cell lymphomas.
Julie M Vose
Lancet (London, England), 378(9806), 1828-1829 (2011-11-29)
View All Related Papers

Global Trade Item Number

SKUGTIN
V4890-25MG04061833227022
V4890-5MG04061833227039

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service